PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 10, 2026Hepatology1 citationsOpen Access

A randomized, double-blind, phase 3, non-inferiority trial of pradefovir mesylate versus tenofovir disoproxil fumarate in chinese patients with chronic hepatitis B

View Full Paper
GYGao YanhangWXWang XinruiWZWang Zhongfeng

Key Points

  • The study aims to evaluate the effectiveness of pradefovir mesylate compared to tenofovir disoproxil fumarate in treating chronic hepatitis B.
  • Randomized, double-blind, phase 3 trial design
  • Comparison of pradefovir mesylate and tenofovir disoproxil fumarate
  • Conducted with Chinese patients diagnosed with chronic hepatitis B
  • Pradefovir mesylate showed comparable effectiveness to tenofovir disoproxil fumarate
  • Pradefovir should be regarded as a highly recommended treatment option for chronic hepatitis B patients

Abstract

Pradefovir should be a highly recommended treatment option for adult patients with CHB.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Yanhang et al. (2026) studied this question.

synapsesocial.com/papers/69d8946e6c1944d70ce055c3https://doi.org/10.1097/hep.0000000000001754
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B2003 · 1,341 citations
  2. 2Efficacy and safety of tenofovir amibufenamide in patients with chronic hepatitis B: a real-world clinical study2026
  3. 3Comparative effectiveness and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in patients with HBV-associated decompensated cirrhosis: insights from a retrospective analysis2025
  4. 4Comparative Efficacy and Renal Safety of Entecavir and Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B: A Retrospective Cohort Study From Vietnam2025 · 2 citations
  5. 5Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB2026 · 2 citations